Benzinga | Sep 29, 2021 06:32AM EDT

Needham Initiates Coverage On Cellebrite DI with Buy Rating, Announces Price Target of $12

Needham analyst Mike Cikos initiates coverage on Cellebrite DI (NASDAQ:CLBT) with a Buy rating and announces Price Target of $12.